Psyence BioMed

Psychedelic medicine developer

Psyence BioMed is a Toronto, Ontario-based clinical-stage biotechnology company developing nature-derived psychedelic medicines. Its investigational botanical psilocybin candidate NPX-5 is in a Phase IIb trial in Australia for adjustment disorder associated with cancer in palliative care. The company is also planning a U.S. ibogaine development program, with a potential clinical trial under evaluation. In October 2026, it announced completion of its PsyLabs investment and a partnership with Benuvia to establish a U.S. pharmaceutical-grade ibogaine manufacturing pathway; its candidates are investigational and not available to buy.

Website

psyencebiomed.com

Psyence BioMed catalog

All products · Psychedelic medicine pipeline

Shop the Psyence BioMed catalog

2 items across 1 shelf

Psychedelic medicine pipeline2 items

• NPX-5 – Botanical psilocybinInvestigational
• Undisclosed – IbogaineInvestigational